You are currently viewing our desktop site, do you want to download our app instead?
Moneyweb Android App Moneyweb iOS App Moneyweb Mobile Web App

NEW SENS search and JSE share prices

More about the app

SA set to use J&J shots

After resolving contract spat. Medicines regulator yet to announce when trial will resume.
Image: Stephen Zenner, Bloomberg

South Africa plans to begin issuing Johnson & Johnson’s coronavirus vaccine to the general public next month after settling a contractual dispute with the U.S. drugmaker.

The outstanding matters relating to the order for 31 million doses were resolved “without compromising the position of South Africa,” Khumbudzo Ntshavheni, an acting minister in the presidency, told reporters following the cabinet’s bi-monthly meeting on Thursday.

Moneyweb Insider INSIDERGOLD

Subscribe for full access to all our share and unit trust data tools, our award-winning articles, and support quality journalism in the process.

Choose an option:

R63 per month
R630 per year SAVE R126

You will be redirected to a checkout page.
To view all features and options, click here.

A monthly subscription is charged pro rata, based on the day of purchase. This is non-refundable and includes a R5 once-off sign-up fee.
A yearly subscription is refundable within 14 days of purchase and includes a 365-day membership.

Click here for more information.

South African Health Minister Zweli Mkhize told parliament last week that J&J wouldn’t sign off on the deal until it received greater assurance of support from the state. The terms insisted on by the company were at times “unreasonable,” he said.

A first batch of 1 million J&J shots being produced at an Aspen Pharmacare plant in the Eastern Cape province is expected to be delivered by April 26, Ntshavheni said. The rollout of shots to people over the age of 60 and other vulnerable groups is set to begin on May 17.

South Africa has also ordered 30 million of the two-dose vaccine developed by Pfizer Inc. and BioNTech SE, which alongside the J&J version should be enough for more than two thirds of the population of about 60 million.

Drug trial
South Africa inoculated 292 623 health workers with the single-dose J&J shots under a drug trial before pausing the programme amid concern over a link to blood clots.

The nation’s medicines regulator has recommended the trial be resumed once specific conditions are met, and Ntshavheni said the health department will make an announcement about when that will happen.

“The temporary suspension in South Africa was in line with government’s commitment to ensure that comprehensive safety measures are undertaken regarding the vaccine rollout,” she said. “The reviewed data confirmed that South Africa has not experienced any rare blood clots with the already vaccinated health-care workers.”

© 2021 Bloomberg L.P.

COMMENTS   2

Sort by:
  • Oldest first
  • Newest first
  • Top voted

You must be signed in to comment.

SIGN IN SIGN UP

It is, and will be one step forward, two or three steps back as long as Ministers and the other ANC hangers on keep interfering and looking for an angle to make a score.

End of comments.

LATEST CURRENCIES  

USD / ZAR
GBP / ZAR
EUR / ZAR
BTC / USD

Podcasts

INSIDER SUBSCRIPTIONS APP VIDEOS RADIO / LISTEN LIVE SHOP OFFERS WEBINARS NEWSLETTERS TRENDING PORTFOLIO TOOL CPD HUB

Follow us:

Search Articles: Advanced Search
Click a Company: